Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Re: The recent paper 'Genetic determinants of impaired awareness of hypoglycaemia in type 1 diabetes'

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Nomenclature for alleles of the human carboxylesterase 1 gene

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Cell-Free Fetal DNA in the Early and Late First Trimester

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Deep neuromuscular blockade and surgical conditions during laparoscopic ventral hernia repair: A randomised, blinded study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Low concentrations of 25-hydroxyvitamin D and long-term prognosis of COPD: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Mutations in the butyrylcholinesterase enzyme (BChE) can result in prolonged duration of action of the neuromuscular blocking agents, succinylcholine and mivacurium, as BChE hydrolyses these drugs. Hereditary low BChE activity can cause extensively prolonged apnoea during general anaesthesia when these drugs are used. The aim of this study was to describe novel mutations in the butyrylcholinesterase gene (BCHE) in patients who have experienced prolonged duration of action of mivacurium or succinylcholine.

METHODS: The Danish Cholinesterase Research Unit registers patients with prolonged duration of action to succinylcholine and mivacurium. Patients were studied if they had equivocal phenotypes on the basis of BChE activity, biochemical inhibitor reactions and with pedigree if possible. Complete nucleotide sequencing was performed to describe the genotype and pedigree was used to separate the alleles. Multiple sequence alignment of BChE was performed for comparison with other species.

RESULTS: Genotyping indicated seven novel mutations in the BCHE (I373T, G467S, W518R, L184S, V421A, M462I and R577H).

CONCLUSION: We have found seven new variants of the BCHE, which seem to reduce the activity of BChE in patients undergoing anaesthesia involving succinylcholine or mivacurium.

OriginalsprogEngelsk
TidsskriftPharmacogenetics and Genomics
Vol/bind26
Udgave nummer7
Sider (fra-til)351-6
Antal sider6
ISSN1744-6872
DOI
StatusUdgivet - jul. 2016

ID: 49819618